As announced earlier, Siegfried Group (SIX:SFZN) has signed an agreement with BASF of Germany concerning the acquisition of significant segments of that company’s pharmaceutical supply business and connected chemical-pharmaceutical production units in France, Germany and Switzerland. The German antitrust authorities (Bundeskartellamt) have now disclosed that it has no reservations concerning the acquisition of three BASF sites by the Siegfried Group, an important precondition for implementation of the agreements. Siegfried, therefore, expects the agreement to be finalized at the beginning of the fourth quarter.
For further information:
Peter Gehler, Chief Communications Officer
Phone: +41 (0)62 746 11 48
Mobile: +41 (0)79 416 41 16
Siegfried Holding AG
Untere Brühlstrasse 4
Phone: +41 (0)62 746 11 11
Fax: +41 (0)62 746 11 03
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 1400 employees. The Siegfried Group signed an agreement with BASF of Germany in May 2015 which, at the beginning of the 4th quarter of 2015, will lead to the acquisition of three sites in France, Germany and Switzerland today owned by BASF. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.